Keryx Biopharmaceuticals Announces Changes to Management and Preliminary First Quarter 2018 Revenue
Keryx Biopharmaceuticals (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that Gregory Madison has resigned as president and chief executive officer of the company and his seat on its board of directors, effective immediately. Jodie Morrison, a member of the company’s board of directors, has been named …
Keryx Biopharmaceuticals (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that Gregory Madison has resigned as president and chief executive officer of the company and his seat on its board of directors, effective immediately. Jodie Morrison, a member of the company’s board of directors, has been named interim chief executive officer. The company also announced preliminary first quarter 2018 revenue.
As quoted in the press release:
“On behalf of the entire board I would like to thank Greg for his contributions to Keryx over the past four years, in particular for his role in transitioning Keryx from a development-stage organization to a commercial entity, and wish him well in his future endeavors,” said Michael Rogers, chairman of Keryx’s board of directors. “We are fortunate to have Jodie – a fellow director – step into a management role and help lead Keryx as we continue to execute on our strategic priorities. We look forward to her continued contributions both as an ongoing member of our board and as interim CEO while we conduct the search for a permanent chief executive officer.”
“We have a very talented leadership team at Keryx and I look forward to working with them to review our business in the coming weeks,” said Jodie Morrison, interim chief executive officer of Keryx. “Auryxia is an important therapy with the potential to benefit millions of people in the U.S. living with chronic kidney disease (CKD) and iron deficiency anemia or hyperphosphatemia. The board and the entire leadership team at Keryx are focused on ensuring that we maximize the value of Auryxia and help as many patients as possible who are living with these complications of CKD.”
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 1846.53 | +0.13 | |
Silver | 21.75 | +0.03 | |
Copper | 4.30 | +0.02 | |
Palladium | 1968.65 | +11.53 | |
Platinum | 957.67 | +3.19 | |
Oil | 110.35 | -1.86 | |
Heating Oil | 3.62 | -0.05 | |
Natural Gas | 8.06 | -0.25 |
DOWNLOAD FREE REPORTS
BROWSE COMPANIES BY SECTOR
- Agriculture Investing
- Phosphate Investing
- Potash Investing
- Base Metals Investing
- Copper Investing
- Iron Investing
- Lead Investing
- Nickel Investing
- Zinc Investing
- Battery Metals Investing
- Cobalt Investing
- Graphite Investing
- Lithium Investing
- Manganese Investing
- Vanadium Investing
- Critical Metals Investing
- Magnesium Investing
- Rare Earth Investing
- Scandium Investing
- Tantalum Investing
- Tellurium Investing
- Tungsten Investing
- Energy Investing
- Oil and Gas Investing
- Uranium Investing
- Gem Investing
- Diamond Investing
- Industrial Metals Investing
- Aluminum Investing
- Chromium Investing
- Coal Investing
- Molybdenum Investing
- Tin Investing
- Precious Metals Investing
- Gold Investing
- Palladium Investing
- Platinum Investing
- Silver Investing
- 3D Printing Investing
- Bitcoin Investing
- Blockchain Investing
- Cleantech Investing
- Cloud Investing
- Cryptocurrencies
- Data Investing
- Emerging Tech Investing
- Artificial Intelligence Investing
- Mobile Investing
- Robotics Investing
- Fintech Investing
- Gaming Investing
- Esports Investing
- Nanoscience Investing
- Graphene Investing
- Nanotech Investing
- Security Investing
Featured stocks
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.